文献速递妇产影像技术与安全

半导体测序平台在胎儿非整倍体无创产前基因筛查中的性能:一项临床环境下的多中心前瞻性队列研究

Performance of semiconductor sequencing platform for non-invasive prenatal genetic screening for fetal aneuploidy: results from a multicenter prospective cohort study in a clinical setting.
PubMed 文献 · Ultrasound Obstet Gynecol · 2019-01-01

该多中心前瞻性队列研究纳入8个学术遗传实验室的2505例孕妇,采用Ion Proton®半导体测序平台和WISECONDOR软件分析血浆游离DNA,评估其对21、18、13三体的筛查性能。21三体敏感度98.3%、特异度99.9%,18三体敏感度96.7%、特异度100%,13三体敏感度94.1%、特异度100%;失败率初为1.2%,部分重测后低至0.6%。

要点

  • Ion Proton平台筛查21三体敏感度98.3%、特异度99.9%,18三体敏感度96.7%、特异度100%,13三体敏感度94.1%、特异度100%。
  • 检测失败率初为1.2%,对部分失败样本重测后低至0.6%。
  • RASSF1A法胎儿分数估算与DEFRAG结果一致,两者均满足常规诊断需求。

核心结论

  • Ion Proton平台在检测三种最常见三体方面高效,流程稳健,可在任何医学遗传实验室轻松实施。

研究设计与样本

  • 多中心前瞻性队列研究,纳入8个学术遗传实验室的2505例孕妇,其中验证研究695例高风险(21三体风险≥1/250)孕妇,真实临床NIPS环境1810例无超声异常的高风险孕妇;验证队列全部有结局,临床队列521例有结局;采用Ion Proton测序仪对血浆游离DNA测序,WISECONDOR软件分析。

诊断标准与关键数值

  • 21三体敏感度98.3%(95%CI 93.5-99.7%)、特异度99.9%(95%CI 99.4-100%);18三体敏感度96.7%(95%CI 80.9-99.8%)、特异度100%(95%CI 99.6-100%);13三体敏感度94.1%(95%CI 69.2-99.7%)、特异度100%(95%CI 99.6-100%);检测失败率初为1.2%,部分重测后低至0.6%。

临床应用与阅片要点

  • 作者描述该平台流程稳健,可在任何医学遗传实验室轻松实施。

局限性

  • 验证队列全部有结局,而临床队列仅521例有结局。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To validate and evaluate the performance metrics of the high-throughput semiconductor sequencing platform, Ion Proton®, in non-invasive prenatal genetic screening (NIPS) for common fetal aneuploidies in a clinical setting.

METHODS: This prospective cohort study included 2505 pregnant women from eight academic genetics laboratories (695 high risk for trisomy 21 (risk ≥ 1/250) pregnancies in a validation study, and 1810 such pregnancies, without ultrasound anomalies, in a real-life NIPS clinical setting). Outcome was available for all cases in the validation cohort and for 521 in the clinical cohort. Cell-free DNA from plasma samples was sequenced using the Ion Proton sequencer, and sequencing data were analyzed using the open-access software, WISECONDOR. Performance metrics for detection of trisomies 21, 18 and 13 were calculated based on either fetal karyotype result or clinical data collected at birth. We also evaluated the failure rate and compared three methods of fetal fraction quantification (RASSF1A assay, and DEFRAG and SANEFALCON software).

RESULTS: Results from both cohorts were consistent and their gestational age was not significantly different so their data were combined to increase the sample size for analysis. Sensitivities and specificities, respectively, were as follows: for trisomy 21, 98.3% (95% CI, 93.5-99.7%) and 99.9% (95% CI, 99.4-100%); for trisomy 18, 96.7% (95% CI, 80.9-99.8%) and 100% (95% CI, 99.6-100%); and for trisomy 13, 94.1% (95% CI, 69.2-99.7%) and 100% (95% CI, 99.6-100%). Our failure rate was 1.2% initially and as low as 0.6% after retesting some of the failed samples. Fetal fraction estimation by the RASSF1A assay was consistent with DEFRAG results, and both were adequate for routine diagnosis.

CONCLUSIONS: We describe one of the largest studies evaluating Ion Proton-based NIPS and the first clinical study reporting pregnancy outcome in a large series of patients. This platform is highly efficient in detecting the three most common trisomies. Our protocol is robust and can be implemented easily in any medical genetics laboratory. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. El Khattabi LA, Brun S, Gueguen P, et al. Performance of semiconductor sequencing platform for non-invasive prenatal genetic screening for fetal aneuploidy: results from a multicenter prospective cohort study in a clinical setting. Ultrasound Obstet Gynecol. 2019. PMID: 30191619. doi:10.1002/uog.20112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。